Yasheng Group (HERB) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Yasheng Group $0.03, price $0.03, upside -11.8%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Yasheng Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0160 – $0.2590 · fair‑value band $0.0300 – $0.0323 · the $0.0340 price screens above the $0.0300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Yasheng in your weekly email
Every Wednesday you see whether Yasheng is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products.
Show more
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products. It cultivates, processes, markets, and distributes various food and agro-byproducts; and manufactures and supplies nutrition and healthcare products. The company's products portfolio includes cotton and wool, sorghum, grains, barley, soybean, alfalfa, corn, and wheat; onions, beets, lupin, bell peppers, potato, peas, carrots, and brussels potato; fuji apple, wolf berry, water melons, apricots, hami melons, peaches, chinese pear, tomato, grapes, dates, yellow river melons, and medlar; hops, nursery crops, liquorices root, flaxseed, aloe plant, TCM herbs, and ginseng; oil seeds, black melon, sunflower, corn; and chicken, pigs, sheep, eggs, and cows. In addition, it produces drip irrigation equipment, fertilizers, and animal feeds; and engages in the acquisition and development of gold, silver, and other mineral properties. The company operates in the United States, the People's Republic of China, and the Philippines. Humanoid, Inc. also exports its products. The company was formerly known as YaSheng Group and changed its name to Humanoid, Inc. in April 2024. The company was founded in 1998 and is headquartered in Sunnyvale, California. Humanoid, Inc. is a subsidiary of Gansu Yasheng Salt Chemical Industrial Group, Ltd.
Stock analysis
Yasheng Group (HERB) currently trades at $0.0340, while our model-based Fair Value estimate is $0.0300, implying the stock looks roughly 13.3% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.2400 per share, and 18 of the 21 models we run sit above the $0.0340 price.
Bear case: the Growth DCF group reads lowest at $0.0300, and 3 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0300 (bear) to $0.0323 (bull), the price of $0.0340 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Yasheng Group reported revenue of $24.1M in FY2024 versus $12.5M in FY2020, a compound +17.8%/yr. Reported net income was $8.1M in FY2024, compounding +28.2%/yr from FY2020.
Key figures
Market cap $5.3M · P/E ratio 0.0 · P/S ratio 0.01 · EPS (TTM) $0.9200 · Net margin 33.4% · Return on equity 2.9% · Return on assets (EBIT) 1.8% · Operating margin 10.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 113% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at −12%, HERB screens richer than that median.
Fair Value models
Bear $0.0300Fair Value $0.0300Bull $0.0323
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then ($0.9200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.7%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
’10
’11
’12
’13
’14
’15
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+39.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+39.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.35% vs −25%, picking up
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 30%
2024 sits 52% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Revenue per share shrinking 24.8%/yr over ~13Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 296 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−12% · Below median
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)33% · Top 25%
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth−25% · Bottom 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Farm Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yasheng Group Fair Value". https://www.fairvalue-calculator.com/stock/HERB
Frequently asked questions
Is Yasheng Group (HERB) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0300 versus a price of $0.0340, about −12% upside (overvalued).
What is the fair value of HERB?
Our model-based fair value for Yasheng Group is $0.0300 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0340.
What is the quality score of HERB?
Yasheng Group has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yasheng Group (HERB)?
Our model-based price target is the fair value of $0.0300 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $0.0300, optimistic scenario $0.0323. It is a calculation from audited fundamentals, not an analyst target.
What is the Yasheng Group stock forecast for 2026?
Our models put fair value at $0.0300, about −12% upside versus a price of $0.0340 (overvalued). Cautious scenario $0.0300, optimistic scenario $0.0323. The calculation is refreshed regularly with new filings.
What is the revenue of Yasheng Group (HERB)?
Yasheng Group reported trailing-twelve-month revenue of about $24.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Yasheng Group (HERB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yasheng Group it is $0.0300 per share (as of Sep 23, 2026), against a price of $0.0340. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Yasheng Group stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HERB trades above its calculated fair value: price $0.0340, fair value $0.0300, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HERB?
No. The price is what the market pays today ($0.0340); the fair value is what the company's own numbers justify ($0.0300). For Yasheng Group the two are $0.0040 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yasheng Group worth?
The market values Yasheng Group at about $5.3M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0340; our models calculate a fair value of $0.0300 per share.
What do the bullish and bearish scenarios say about HERB?
Our models span a range for Yasheng Group: cautious scenario $0.0300, base $0.0300, optimistic $0.0323 per share (as of Sep 23, 2026, price $0.0340). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HERB?
Yasheng Group trades at a price-to-earnings ratio of 0.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0300 is built from several models across several years.
How solid is the balance sheet of Yasheng Group (HERB)?
Balance-sheet figures for Yasheng Group (as of Sep 23, 2026): return on equity 2.9%, debt of 0.16 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is HERB from its 52-week high?
Yasheng Group trades at $0.0340, about 35% below its 52-week high of $0.0520 and 113% above the low of $0.0160 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.
Which stocks are comparable to Yasheng Group?
From the same area (Consumer Defensive) we also value Archer-Daniels-Midland Company, Muyuan Foods Group, Bunge Global SA, Tyson Foods, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yasheng Group stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0340, calculated fair value $0.0300 (−12%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HERB calculated?
We run Yasheng Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Yasheng Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yasheng Group (HERB)?
The closing price on Sep 22, 2026 was $0.0340. Our model-based fair value is $0.0300, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yasheng Group right now?
The price sits above even our optimistic bull case ($0.0323). The favourable scenario is already priced in. The models converge in a tight band ($0.0300 to $0.0323), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Yasheng Group (HERB) come from?
Earnings per share at Yasheng Group grew −30.4 % a year from 2012 to 2023. Broken into its drivers: revenue per share −36.4 %, EBIT margin +8.3 %, tax rate −3.8 %, residual (interest, one-offs) +5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Yasheng Group
How large is the market capitalisation of Yasheng Group (HERB)?
The market capitalisation of Yasheng Group is $5.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yasheng Group (HERB)?
The price-to-sales ratio of Yasheng Group is 0.01 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yasheng Group (HERB)?
Earnings per share at Yasheng Group are $0.9200 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Yasheng Group (HERB)?
The net margin of Yasheng Group is 33.4% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yasheng Group (HERB)?
The return on equity (ROE) of Yasheng Group is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yasheng Group (HERB)?
On an EBIT basis the return on assets of Yasheng Group is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yasheng Group (HERB)?
The operating margin of Yasheng Group is 10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yasheng Group (HERB)?
Revenue at Yasheng Group is growing −24.5% versus a year earlier (3y avg +19.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yasheng Group (HERB)?
Earnings per share at Yasheng Group are growing −53.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yasheng Group (HERB) generate?
The free cash flow of Yasheng Group is $2.7M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Yasheng Group (HERB) hold?
Yasheng Group holds more cash than debt, $8.3M net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Yasheng Group in the live analysis
One click puts Yasheng Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026